从分子建模角度深入了解组织蛋白酶 S 抑制剂的选择性抑制作用。
Insights from molecular modeling into the selective inhibition of cathepsin S by its inhibitor.
机构信息
Molecular and Structural Biology Division, CSIR-Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India.
Academy of Scientific and Innovative Research (AcSIR), CSIR-Central Drug Research Institute, Campus, Lucknow, 226031, India.
出版信息
J Mol Model. 2017 Mar;23(3):92. doi: 10.1007/s00894-017-3255-6. Epub 2017 Feb 24.
Cathepsin S has been demonstrated to play a crucial role in the remodeling of extracellular matrix proteins such as elastin and collagen, which in turn contribute to the structural integrity of the cardiovascular wall. Atherosclerotic lesions, aneurysm formation, plaque rupture, thrombosis, and calcification are some of the cardiovascular disorders related to cathepsin S. A highly selective inhibitor of human as well as animal cathepsin S, RO5444101, was recently reported to attenuate the progression of atherosclerotic lesions. Here, we attempted to gain insight into the molecular mechanism of action of RO5444101 on cathepsin S by performing molecular docking and molecular dynamics (MD) simulation studies. The results of our studies correlate well with relevant reported experimental data and potentially explain the selectivity of this inhibitor for cathepsin S rather than cathepsin L1/L, cathepsin L2/V, and cathepsin K, which share conserved catalytic sites and have sequence similarities of 49%, 50%, and 55%, respectively, with respect to cathepsin S. In contrast to those closely related cathepsins, 20 ns MD simulation data reveal that the overall interaction of cathepsin S with RO5444101 is more stable and involves more protein-molecule interactions than the interactions of the inhibitor with the other cathepsins. This study therefore considerably improves our understanding of the molecular mechanism responsible for cathepsin S inhibition and facilitates the identification of potential novel selective inhibitors of cathepsin S.
组织蛋白酶 S 已被证明在细胞外基质蛋白(如弹性蛋白和胶原蛋白)的重塑中发挥关键作用,而这些蛋白又有助于心血管壁的结构完整性。与组织蛋白酶 S 相关的心血管疾病包括动脉粥样硬化病变、动脉瘤形成、斑块破裂、血栓形成和钙化等。最近有报道称,一种对人源和动物源组织蛋白酶 S 均具有高度选择性的抑制剂 RO5444101 可减轻动脉粥样硬化病变的进展。在这里,我们尝试通过进行分子对接和分子动力学(MD)模拟研究,深入了解 RO5444101 对组织蛋白酶 S 的作用机制。我们的研究结果与相关的实验数据相吻合,并且可能解释了该抑制剂对组织蛋白酶 S 的选择性,而不是对组织蛋白酶 L1/L、组织蛋白酶 L2/V 和组织蛋白酶 K 的选择性,这三种酶与组织蛋白酶 S 具有保守的催化位点,并且序列相似性分别为 49%、50%和 55%。与这些密切相关的组织蛋白酶不同,20ns MD 模拟数据显示,组织蛋白酶 S 与 RO5444101 的整体相互作用更稳定,并且涉及更多的蛋白质-分子相互作用,而抑制剂与其他组织蛋白酶的相互作用则较少。因此,这项研究极大地提高了我们对组织蛋白酶 S 抑制的分子机制的理解,并有助于鉴定潜在的新型组织蛋白酶 S 选择性抑制剂。